依帕珠单抗和钇-90标记的依帕珠单抗，用于B细胞非霍奇金淋巴瘤。
Epratuzumab and 90Y Epratuzumab for B cell non-Hodgkin lymphoma.
细胞非霍奇金淋巴瘤组织CD 22表达和临床病理特征的关系需进一步研究。
CD22 expression in B cell NHL tissue and its relationship with clinicopathological characteristics needs further study.
目的评价德国NHL-BFM-90方案治疗中国儿童青少年B细胞非霍奇金淋巴瘤（B-NHL）的疗效和毒性。
Objectives To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas(B-NHL).
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
共有65%的个体经历了恶性肿瘤包括肾母细胞瘤，神经母细胞瘤，非霍奇金淋巴瘤，与中枢神经系统肿瘤的辐射。
A total of 65% had undergone radiation for malignancies including nephroblastoma, neuroblastoma, non-Hodgkin's lymphoma, and tumors of the central nervous system.
滤泡性B细胞淋巴瘤是一种非霍奇金淋巴瘤，肿瘤疫苗是治疗是根据肿瘤细胞的生物学特殊性。
The cancer vaccines rely on a biological quirk of follicular B-cell lymphoma, which is a type of non-Hodgkin's lymphoma.
可见大的蓝色的非霍奇金淋巴瘤细胞浸润黏膜层。
The large blue non-Hodgkin's lymphoma cells can be seen infiltrating through the mucosa.
RIT最早是用作癌症治疗而开发，目前在治疗起源于免疫细胞的非霍奇金淋巴瘤上获得很大成功。
RIT was first developed for cancer treatment, the current in the treatment of immune cells originate from non-Hodgkin's lymphoma received a great success.
目的了解多中心协作化疗方案(MCP方案)对急性淋巴细胞白血病(all)和非霍奇金淋巴瘤(NHL)患儿肾脏功能的影响。
Objective to investigate the renal damages in children with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) who received the intensive multicenter-protocols (MCP).
目的：观察国产表柔比星为主的联合化疗方案治疗非霍奇金淋巴瘤、乳腺癌、非小细胞肺癌的疗效和不良反应。
Objective:To observe the efficacy and toxicity of domestic epirubicin in treatment of non Hodgkin's lymphoma, breast cancer, and non small cell lung cancer.
组织学形态均为恶性弥漫性非霍奇金淋巴瘤，免疫表型B细胞来源9例，T细胞来源1例。
Histologicallly, all cases were diffuse non - Hodgkin lymphoma. 9 cases were B and 1 case were t immunophenotype.
克隆性免疫球蛋白重链基因重排检测可以作为诊断恶性B细胞性非霍奇金淋巴瘤的有效分子标志。
Clonal immunoglobulin heavy chain gene rearrangement can be used as a effective diagnostic molecular marker for B-NHL.
为了评价T细胞淋巴瘤患者的转归与预后，我们分析了德国高度非霍奇金淋巴瘤研究小组（DSHNHL）进行的临床试验中治疗的343例患者。
To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
它对血细胞的毒性作用已得到很好地记载，而且已知它导致不同类型的白血病、多发性骨髓瘤和非霍奇金淋巴瘤。
Its toxic effects on blood cells are well documented and it's known to cause different kinds of leukaemia, multiple myeloma and non-Hodgkin lymphoma.
它对血细胞的毒性作用已得到很好地记载，而且已知它导致不同类型的白血病、多发性骨髓瘤和非霍奇金淋巴瘤。
Its toxic effects on blood cells are well documented and it's known to cause different kinds of leukaemia, multiple myeloma and non-Hodgkin lymphoma.
应用推荐